Table 1

Measurements of efficacy at baseline, week 8, week 16 and week 24

MeasurementsBaselineWeek 8Week 16Week 24
PASI11.8 (10.0–26.6)2.7 (0.4–5.4)*1.8 (0.0–4.0)*1.2 (0.0–4.0)*
Patient global assessment (VAS, mm)50 (20–82)30 (5–50)*25 (0–40)*15 (0–40)*
Patient skin assessment (VAS, mm)50 (30–94)32 (15–50)*14 (0–37)*10 (0–37)*
Physician global assessment (VAS, mm)45 (10–71)25 (5–53)*15 (0–42)*10 (0–32)*
Physician skin assessment (VAS, mm)53 (23–81)22 (8–40)*10 (0–42)*8 (0–42)*
Tender joints (n)0 (0–2)0 (0–2)0 (0–1)0 (0–1)
Swollen joints (n)0 (0–1)0 (0–1)0 (0–1)0 (0–1)
Dactylitis (n)0 (0–0)0 (0–0)0 (0–0)0 (0–0)
MASES0 (0–2)0 (0–0)0 (0–0)0 (0–0)
ESR (mm/h)14 (11–45)16 (2–42)16 (4–40)18 (6–40)
CRP (mg/l, normal <5.0)4.5 (0.4–14.0)3.0 (0.4–15.0)3.5 (0.5–7.0)3.0 (0.6–5.1)
  • Values are median (range).

  • * p<0.05 (Wilcoxon test vs baseline).

  • CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score7; PASI, Psoriasis Area and Severity Index6; VAS, visual analogue scale ranging from 0 (very well) to 100 mm (very poor).